Glucagon-like peptide-1 (GLP-1) receptor agonists are used to treat diabetes, but their effects on nonalcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) remain unclear. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.